Connection
Christina Aquilante to Hydroxymethylglutaryl-CoA Reductase Inhibitors
This is a "connection" page, showing publications Christina Aquilante has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.793 |
|
|
|
-
Aquilante CL, Wempe MF, Sidhom MS, Kosmiski LA, Predhomme JA. Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers. Eur J Clin Pharmacol. 2013 Jul; 69(7):1401-9.
Score: 0.295
-
Aquilante CL, Kiser JJ, Anderson PL, Christians U, Kosmiski LA, Daily EB, Hoffman KL, Hopley CW, Predhomme JA, Schniedewind B, Sidhom MS. Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin. J Clin Pharmacol. 2012 Nov; 52(11):1725-38.
Score: 0.272
-
Kao DP, Martin JL, Aquilante CL, Shalowitz EL, Leyba K, Kudron E, Reusch JEB, Regensteiner JG. Sex-differences in reporting of statin-associated diabetes mellitus to the US Food and Drug Administration. BMJ Open Diabetes Res Care. 2024 Dec 05; 12(6).
Score: 0.167
-
Daily EB, Aquilante CL. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009 Sep; 10(9):1489-510.
Score: 0.058